grazoprevir + peginterferon alfa-2b + ribavirin

This combination drug contains three antiviral agents: **grazoprevir**, **peginterferon alfa-2b**, and **ribavirin**. Grazoprevir is a direct-acting antiviral (DAA) and a hepatitis C virus (HCV) NS3/4A protease inhibitor, which blocks HCV replication. Peginterferon alfa-2b is a pegylated recombinant interferon that exerts antiviral and immunomodulatory effects by binding to type I interferon receptors, activating Jak-STAT pathways, and inducing expression of antiviral proteins. Ribavirin is a nucleoside analogue with broad-spectrum antiviral activity that inhibits viral RNA synthesis and modulates the host immune response. This combination is primarily under investigation for the treatment of **chronic hepatitis C infection**, especially in patients with difficult-to-treat genotypes or in those who have failed previous therapies. While peginterferon alfa-2b and ribavirin are an established backbone for HCV regimens, the addition of grazoprevir is intended to increase antiviral efficacy, particularly against HCV genotype 1 and genotype 4.

Other names

grazoprevir + PEG-IFN + RBVgrazoprevir/pegylated interferon/ribavirin